Also trades as: 1548.HK (HKSE) · $vol 194M
GNNSF OTC
Genscript Biotech Corporation
1W: +9.3%
1M: +18.7%
3M: +245.0%
YTD: +200.0%
1Y: +145.3%
3Y: +160.4%
5Y: +174.6%
$5.52
-0.18 (-3.16%)
Weekly Expected Move ±14.5%
$4
$5
$6
$6
$7
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$961M
+61.6% ▲
5Y CAGR: +19.7%
Gross Profit
$554M
+103.6% ▲
5Y CAGR: +16.7%
Operating Income
$256M
+2654.0% ▲
Net Income
-$534M
-118.0% ▼
EPS (Diluted)
$-0.25
-118.4% ▼
EBITDA
$330M
+370.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $511M | $626M | $840M | $594M | $961M |
| YoY Growth | +30.8% | +22.4% | +34.2% | -29.2% | +61.6% |
| Cost of Revenue | $208M | $322M | $430M | $322M | $407M |
| Gross Profit | $283M | $304M | $410M | $272M | $554M |
| Gross Margin | 55.3% | 48.6% | 48.8% | 45.8% | 57.7% |
| R&D Expenses | $358M | $390M | $434M | $54M | $71M |
| SG&A Expenses | $302M | $351M | $388M | $202M | $227M |
| Operating Expenses | $652M | $742M | $825M | $263M | $298M |
| Operating Income | -$368M | -$436M | -$416M | $9M | $256M |
| Operating Margin | -72.1% | -69.7% | -49.5% | 1.6% | 26.6% |
| Interest Expense | $2M | $13M | $28M | $8M | $17M |
| Income Before Tax | -$517M | -$432M | -$351M | -$171M | -$471M |
| Tax Expense | $964K | -$4M | $4M | $3M | $62M |
| Net Income | -$359M | -$227M | -$95M | $3.0B | -$534M |
| Net Margin | -70.2% | -36.3% | -11.4% | 498.2% | -55.5% |
| EPS (Diluted) | $-0.18 | $-0.11 | $-0.05 | $1.36 | $-0.25 |
| EBITDA | -$466M | -$355M | -$249M | $70M | $330M |
| Shares Outstanding | 2.03B | 2.10B | 2.11B | 2.18B | 2.17B |